All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Aman, 2021 0.51 [0.27; 0.96]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Gharebaghi, 2020 0.00 [0.00; 0.09]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Shi, 2020 0.53 [0.01; 27.55]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
0.68 [0.48 ; 0.97 ] Aman, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Gharebaghi, 2020, Kalil (ACTT-3), 2021, NCT04377750 (HMO-0224-20), 0, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 12 48% 3,327 moderate critical death or transfer to ICUdetailed results Lopardo, 2021 0.65 [0.35; 1.22]
0.65 [0.35 ; 1.22 ] Lopardo, 2021 1 0% 241 NA not evaluable deathsdetailed results Aman, 2021 0.51 [0.27; 0.96]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
COLCHIVID, 2021 0.69 [0.20; 2.40]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
DEVENT, 0 0.47 [0.22; 1.00]
Gharebaghi, 2020 0.00 [0.00; 0.09]
ILBS-COVID-02 (Bajpai M), 2020 3.82 [0.35; 41.96]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Lopardo, 2021 0.57 [0.24; 1.37]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
Shi, 2020 0.53 [0.01; 27.55]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
0.74 [0.58 ; 0.95 ] Aman, 2021, CAPE-COVID, 2020, COLCHIVID, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, DEVENT, 0, Gharebaghi, 2020, ILBS-COVID-02 (Bajpai M), 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Lopardo, 2021, NCT04377750 (HMO-0224-20), 0, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 21 39% 4,657 moderate low deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
1.04 [0.80 ; 1.35 ] COVACTA (Rosas), 2020, Kalil (ACTT-3), 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021 4 0% 2,395 moderate not evaluable clinical improvementdetailed results COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.15 [0.98 ; 1.35 ] COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 11 27% 2,847 moderate critical clinical improvement (14-day)detailed results COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
1.29 [0.69 ; 2.41 ] COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021 2 66% 1,070 moderate not evaluable clinical improvement (28-day)detailed results COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
O’Donnell, 2021 1.38 [0.73; 2.61]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.34 [1.00 ; 1.81 ] COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, O’Donnell, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 5 0% 787 moderate serious clinical improvement (time to event analysis only)detailed results Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
1.03 [0.93 ; 1.14 ] Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 2020 5 0% 2,032 moderate not evaluable death or ventilationdetailed results CAPE-COVID, 2020 0.71 [0.37; 1.35]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82]
sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
0.72 [0.49 ; 1.07 ] CAPE-COVID, 2020, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 4 45% 1,068 moderate not evaluable hospital dischargedetailed results CAPE-COVID, 2020 1.67 [0.87; 3.19]
COLCHIVID, 2021 1.13 [0.76; 1.67]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
1.08 [0.85 ; 1.36 ] CAPE-COVID, 2020, COLCHIVID, 2021, Rosas (REMDACTA), 2021 3 24% 924 low not evaluable mechanical ventilationdetailed results CAPE-COVID, 2020 0.95 [0.44; 2.04]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71]
sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
0.58 [0.36 ; 0.94 ] CAPE-COVID, 2020, COVACTA (Rosas), 2020, O’Donnell, 2021, PlasmAr, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 8 43% 1,273 moderate not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
Lopardo, 2021 0.67 [0.35; 1.28]
0.57 [0.36 ; 0.91 ] COVACTA (Rosas), 2020, Lopardo, 2021 2 0% 432 moderate not evaluable off oxygenationdetailed results ILBS-COVID-02 (Bajpai M), 2020 0.26 [0.02; 2.88]
sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15]
sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.27 [0.62 ; 2.60 ] ILBS-COVID-02 (Bajpai M), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 3 39% 299 serious not evaluable recoverydetailed results COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
1.57 [0.77 ; 3.20 ] COV-BARRIER (critically ill), 2022 1 0% 101 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Shi, 2020 1.08 [0.04; 32.96]
0.94 [0.76 ; 1.15 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Shi, 2020 7 5% 2,234 moderate not evaluable superinfectiondetailed results CAPE-COVID, 2020 0.81 [0.49; 1.34]
0.81 [0.49 ; 1.34 ] CAPE-COVID, 2020 1 0% 149 NA not evaluable adverse eventsdetailed results COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Shi, 2020 0.88 [0.38; 2.03]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
1.08 [0.83 ; 1.39 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Shi, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 7 13% 1,707 moderate serious 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-14 13:56 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 91
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290
